EmpathBio, Inc.

Pipeline (1)

• EMP-01 (oral R-MDMA)PsychedelicSERT Releaser
  • Social anxiety disorderPhase 2Completed

Deals & partnerships

• EMP-01 (oral R-MDMA)Partner Neuphoria Therapeutics, Inc.

• Feb 17, 2021PartnershipEmpathBio (atai) and Bionomics MOU for joint feasibility assessment of EMP-01 + BNC210 in PTSDEmpathBio, a wholly-owned subsidiary of atai Life Sciences, and Bionomics signed a Memorandum of Understanding to collectively explore a combination drug treatment regimen pairing EmpathBio's MDMA derivative EMP-01 with Bionomics' BNC210 (a non-sedating anxiolytic) for the treatment of PTSD, beginning with preclinical feasibility studies. The parties indicated intent to negotiate a definitive binding agreement for clinical trials if exploratory results proved promising.EMP-01 (oral R-MDMA)source ↗

Recent activity

• Feb 12, 2026Phase changeEMP-01 (oral R-MDMA)·Social anxiety disorderPhase 2Phase 2a SAD trial completed; positive topline (large SPIN/SAFE/LSAS improvements).source ↗
• Apr 15, 2025Phase changeEMP-01 (oral R-MDMA)·Social anxiety disorderPhase 2Phase 2a exploratory SAD study (NCT06693609) initiated; first patient dosed announced May 2025.source ↗
• Sep 27, 2022Phase changeEMP-01 (oral R-MDMA)·Social anxiety disorderPhase 1Phase 1 single-ascending-dose trial of oral EMP-01 initiated in healthy volunteers.source ↗

Competitive landscape

Other companies developing against EmpathBio, Inc.'s targets or indications.

• Definium Therapeutics, Inc.1 compoundSERT
• Hoffmann-La Roche1 compoundSocial anxiety disorder
• Neuphoria Therapeutics, Inc.1 compoundSocial anxiety disorder
• Otsuka Pharmaceutical Co., Ltd.1 compoundSERT
• Transcend Therapeutics, Inc.1 compoundSERT
• Vanda Pharmaceuticals Inc.1 compoundSocial anxiety disorder
• Vistagen Therapeutics, Inc.1 compoundSocial anxiety disorder

Leadership & advisors (1)

• Glenn Short, Ph.D.Chief Executive Officer